Drug addiction: a critical problem calling for novel solutions

Clin Pharmacol Ther. 2008 Apr;83(4):503-6. doi: 10.1038/clpt.2008.11.
No abstract available

Publication types

  • Editorial
  • Introductory Journal Article
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Benzazepines / therapeutic use
  • Buprenorphine / therapeutic use
  • Bupropion / therapeutic use
  • Chronic Disease
  • Financing, Government
  • Genetic Testing
  • Harm Reduction
  • Humans
  • Marijuana Smoking
  • Naltrexone / therapeutic use
  • Narcotic Antagonists / therapeutic use
  • Prevalence
  • Privacy
  • Quinoxalines / therapeutic use
  • Receptors, Nicotinic / drug effects
  • Recurrence
  • Risk-Taking
  • Smoking / economics
  • Smoking / epidemiology
  • Smoking Cessation / economics*
  • Smoking Prevention
  • Social Environment
  • Substance-Related Disorders* / economics
  • Substance-Related Disorders* / epidemiology
  • Substance-Related Disorders* / genetics
  • Substance-Related Disorders* / prevention & control
  • Varenicline

Substances

  • Benzazepines
  • Narcotic Antagonists
  • Quinoxalines
  • Receptors, Nicotinic
  • Bupropion
  • Buprenorphine
  • Naltrexone
  • Varenicline